All In Biotech

Drug Trial Radar · NCT06790303

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2

A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants

Last checked: Nov 19, 2026Latest source record: Jun 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

8

Actual

Start

Mar 4, 2021

Primary completion

Sep 23, 2021

Study completion Sep 23, 2021

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jan 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess the clinical activity of novel regimen (Feladilimab plus Ipilimumab) in participants with NSCLC.

Conditions

  • Neoplasms

Interventions

  • FeladilimabDrug

    Feladilimab will be administered.

  • IpilimumabDrug

    Ipilimumab will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 29 weeks
  2. Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to 21 days
  3. Part 1: Number of Participants With Worst-case Change Post-baseline in Hematology ParametersTime frame: Baseline (Day 1) and up to 29 weeks
  4. Part 1: Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry ParametersTime frame: Baseline (Day 1) and up to 29 weeks
  5. Part 1: Number of Participants With Worst Case Change Post-baseline in Urinalysis ParametersTime frame: Baseline (Day 1) and up to 29 weeks
  6. Part 1: Change From Baseline in Potential of Hydrogen (pH) of UrineTime frame: Baseline (Day 1), week 4, week 7, week 10, week 13 and week 29 (Treatment Discontinuation)
  7. Part 1: Change From Baseline in Specific Gravity of UrineTime frame: Baseline (Day 1), week 4, week 7, week 10, week 13 and week 29 (Treatment Discontinuation)
  8. Part 1: Number of Participants With AE Leading to Dose ModificationsTime frame: Up to 29 weeks
  9. Part 2: Overall SurvivalTime frame: Up to 29 weeks

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    Brampton, Ontario, Canada

  • GSK Investigational Site

    Bordeaux, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.